Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Ranibizumab

Brand: Lucentis┬«
NICE TA: 298
Indication: Choroidal neovascularisation (pathological myopia) (NICE TA298)
Disease category: Eye
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme. Ranibizumab is an alternative treatment option to verteporfin photodynamic therapy (vPDT) and bevacizumab.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red